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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2005.08.050Objective: Thrombin is generated in significant quantities during cardiopulmonary
bypass and mediates adverse events, such as platelet aggregation and proinflammatory
responses, through activation of the high-affinity thrombin receptor protease-activated
receptor 1, which is expressed on platelets and endothelium. Thus antagonism of
protease-activated receptor 1 might have broad therapeutic significance. Aprotinin,
used clinically to reduce transfusion requirements and the inflammatory response to
bypass, has been shown to inhibit protease-activated receptor 1 on platelets in vitro
and in vivo. Here we have examined whether aprotinin inhibits endothelial protease-
activated receptor 1 activation and resulting proinflammatory responses induced by
thrombin.
Methods: Protease-activated receptor 1 expression and function were examined in
cultured human umbilical vein endothelial cells after treatment with -thrombin at
0.02 to 0.15 U/mL in the presence or absence of aprotinin (200-1600 kallikrein
inhibitory units/mL). Protease-activated receptor 1 activation was assessed by using
an antibody, SPAN-12, which detects only the unactivated receptor, and thrombin-
mediated calcium fluxes. Other thrombin-dependent inflammatory pathways inves-
tigated were phosphorylation of the p42/44 mitogen-activated protein kinase, up-
regulation of the early growth response 1 transcription factor, and production of the
proinflammatory cytokine interleukin 6.
Results: Pretreatment of cultured endothelial cells with aprotinin significantly spared
protease-activated receptor 1 receptor cleavage (P  .0001) and abrogated calcium
fluxes caused by thrombin. Aprotinin inhibited intracellular signaling through p42/44
mitogen-activated protein kinase (P  .05) and early growth response 1 transcription
factor (P  .05), as well as interleukin 6 secretion caused by thrombin (P  .005).
Conclusions: This study demonstrates that endothelial cell activation by thrombin
and downstream inflammatory responses can be inhibited by aprotinin in vitro
through blockade of protease-activated receptor 1. Our results provide a new molecular
basis to help explain the anti-inflammatory properties of aprotinin reported clinically.
Cardiopulmonary bypass (CPB), although remaining an indispensable asset incardiac surgery, is associated with significant thrombin generation in the bypasscircuit.1,2 Sternotomy might also contribute to the increase in thrombin.3
Thrombin is a multifunctional serine protease that plays a crucial role in the
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coagulation and inflammatory systems. Its presence during
bypass leads to platelet dysfunction and excessivet bleeding
postoperatively and might be implicated in the systemic
inflammatory response and perioperative stroke.3-5
Thrombin can trigger cellular responses in a variety of
cell types through activation of a family of 7 transmem-
brane-spanning G protein–coupled receptors known as pro-
tease-activated receptors (PARs). Thrombin activates PAR1
by means of proteolytic cleavage, exposing a new amino
terminus that serves as a tethered ligand by binding to sites
within the body of the receptor.6 Synthetic peptides corre-
sponding to the amino terminus of the tethered ligand can
act as ligand mimetics and bypass the need for receptor
cleavage. The best characterized example of such a peptide
is the thrombin receptor agonist peptide (TRAP) 6, which is
specific for human PAR1.7
Endothelial cells play a critical role in the regulation of
thrombosis and inflammation, which can become dysregu-
lated after CPB.4 Thrombin signaling in the endothelium
regulates permeability, vascular tone, leukocyte trafficking
and inflammation, formation of new vessels, and hemosta-
sis. Of the 3 human thrombin receptors, PAR1, PAR3, and
PAR4, identified thus far, PAR1 is the predominant form
expressed on endothelial cells8 and is also widely expressed
on platelets, on smooth muscle cells, and in the central
nervous system.9-11 Activation of PAR1 by thrombin has
been shown to mediate many adverse events seen after CPB,
such as platelet aggregation, inflammatory cytokine secretion,
and neurodegeneration.10-13 PAR1 activation triggers a n u m -
ber of signaling pathways that include G protein–coupled
calcium flux and phosphorylation (ie, activation) of the
signaling protein p42/44 mitogen-activated protein (MAP)
kinase, protein kinase C, phosphatidylinositol 3 kinase, and
the early growth response (Egr) 1 transcription factor.10,13,14
There is presently great interest in blocking the signaling
pathways downstream of PAR1 pharmacologically, and sev-
eral classes of PAR1 antagonists are in preclinical trials.15,16
Interleukin (IL) 6 is an acute-phase inflammatory cyto-
Abbreviations and Acronyms
CPB  cardiopulmonary bypass
Egr  early growth response
HRP  horseradish peroxidase
HUVEC human umbilical vein endothelial cell
IL  interleukin
KIU  kallikrein inhibitory units
MAP mitogen-activated protein
PAR  protease-activated receptor
SD  standard deviation
TRAP  thrombin receptor agonist peptidekine that plays a critical role in leukocytosis, thrombosis,
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activated endothelial cells, macrophages, fibroblasts, and
adipocytes. Plasma IL-6 levels are strongly induced at 3 to
4 hours after CPB, and IL-6 was shown to be the most
highly upregulated gene (41-fold increase) by means of
microarray analysis of 12,625 genes in patients undergoing
CPB and cardioplegic arrest.18,19 A promoter polymorphism
that leads to abnormally high levels of IL-6 has been linked
to an exacerbated systemic inflammatory response and atrial
fibrillation after CPB.20 Because thrombin is known to
stimulate IL-6 secretion by endothelial cells in vitro through
PAR1,21 this source of IL-6 production might be of clinical
relevance to the inflammatory complications of CPB.
The protease inhibitor aprotinin, already approved for
clinical use to limit transfusion requirements in cardiac
surgery, has been shown to block PAR activation on
platelets, both in vitro and in vivo.22-24 We hypothesize
that the anti-inflammatory properties of aprotinin in CPB
might be mediated, at least in part, through an ablation of
thrombin-mediated PAR1 signals on endothelial cells. In
the present study we demonstrate that aprotinin blocks
PAR1-mediated signaling and IL-6 secretion in endothe-
lial cells in vitro.
Materials and Methods
Antibodies
-Thrombin and anti--tubulin antibody were purchased from
Sigma-Aldrich (Poole, United Kingdom). Polyclonal rabbit anti-
bodies against phosphorylated or total p42/44 MAP kinase protein
and secondary horseradish peroxidase (HRP)–linked sheep anti-
rabbit antibody were purchased from Cell Signaling Technologies
(Hitchin, United Kingdom). Anti-Egr-1 antibody was purchased
from Santa Cruz Biotechnology, Inc (Middlesex, United King-
dom). Secondary HRP-linked sheep anti-mouse antibody was pur-
chased from Amersham Pharmacia Biosciences (Chalfont St Giles,
United Kingdom). TRAP-6 was purchased from Bachem (UK) Ltd
(St Helens, United Kingdom).
Endothelial Cells
Human umbilical vein endothelial cells (HUVECs) were isolated
from umbilical veins by means of collagenase II digestion (0.1%;
Boehringer-Mannhein, Lewes, Sussex, United Kingdom), as pre-
viously described.13 HUVECs were cultured in 75-cm2 flasks and
used between passages 2 and 4. At confluence, cells were detached
with cell dissociation medium (Sigma Aldrich), a trypsin-free
detachment step that avoids possible PAR activation by trypsin.
PAR1 Receptor Cleavage Assay
Receptor cleavage after thrombin activation was assessed by
means of flow cytometry with an antibody, SPAN-12 (Beckman-
Coulter, Luton, United Kingdom), that detects only the intact (ie,
unactivated) PAR1 receptor. Loss of SPAN-12 staining therefore
provides a linear measure of receptor activation. SPAN-12 staining
was carried out on freshly passaged cells in suspension after
-thrombin stimulation (0.02 U/mL) for 5 minutes at 37°C with or
without 200 kallikrein inhibitory units (KIU)/mL aprotinin. All
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Psteps after addition of SPAN-12 antibody were carried out on ice
to prevent internalization of cleaved receptor. SPAN-12 staining
(10 g/mL) was performed for 15 minutes, followed by 3 washes
in ice-cold phosphate-buffered saline. Secondary antibody staining
with fluorescein isothiocyanate–conjugated goat anti-mouse IgG
antibody (1:64 dilution) was carried out for 15 minutes, followed
by 3 washes in ice-cold phosphate-buffered saline and fixation
with 2% paraformaldehyde. Flow cytometric analysis was per-
formed with an EPICS XL flow cytometer (Coulter Electronics
Ltd, Luton, United Kingdom). SPAN-12 staining was expressed in
units of relative fluorescent intensity (RFI), which are calculated
by dividing the mean fluorescent staining intensity obtained with
SPAN-12 antibody by the staining intensity of a class-matched
control antibody (ie, an RFI of 1.00 is equivalent to no detectable
expression). Results were presented as mean SPAN-12 expression
(RFI units)  standard deviation (SD) from 9 experiments.
Calcium Flux
Endothelial cells in suspension were loaded with Fura-2 AM
(5 mol/L; Molecular Probes Inc, Eugene, Ore) for 1 hour at 37°C
and adjusted to 4  106 cells/mL. Intracellular Ca2 fluxes were
determined by measuring Fura-2 fluorescence at 340 nm excitation
and 510 nm emission with an LS 50 B spectrofluorimeter (Perkin
Elmer, Beaconsfield, United Kingdom).
Immunoblotting
Western blotting was carried out as previously described.25
Briefly, HUVECs were serum starved for 3 hours (in medium
M199 supplemented with 2% bovine serum albumin) before stim-
ulation with thrombin (0.15 U/mL). Preliminary experiments in-
dicated that maximum p42/44 protein phosphorylation occurred at
10 minutes and Egr-1 upregulation occurred at 1 hour after throm-
bin addition, and cell lysates were therefore collected at 10 minutes
in the case of p42/44 MAP kinase and 1 hour in the case of Egr-1
in buffer containing 50 mmol/L Tris/HCL (pH 7.4), 150 mmol/L
NaCl, 1% Triton X-100, 25 mmol/L sodium deoxycholic acid,
4 mmol/L ethylenediamine tetraacetic acid, 200 mol/L sodium
orthovanadate, 10 mmol/L sodium pyrophosphate, 100 mmol/L
sodium fluoride, 1 mmol/L phenylmethylsulfonyl fluoride, and 5%
protease inhibitor cocktail (Sigma Aldrich). The protein content in
lysates was first determined by using a Bio-Rad Dc protein assay
(Bio-Rad, Hercules, Calif) to achieve equal protein loading into
wells. Proteins were resolved by means of sodium dodecylsulfate–
polyacrylamide gel electrophoresis and semidry blotted onto
Immobilon-P membranes (Millipore Corp, Bedford, Mass). The
membrane was then incubated with relevant primary antibodies
overnight at 4°C, washed 3 times in Tris-buffered saline/0.1%
Tween 20, and incubated for 1 hour at room temperature with an
appropriate HRP-labeled secondary antibody. Blots were devel-
oped with enhanced chemiluminescence reagent (Amersham Bio-
sciences) and exposed to autoradiography film. Films were
scanned densitometrically with a ChemiImager 500 (Alpha Inno-
tech Corp, San Leandro, Calif) to obtain a signal intensity in units
of integrated density value. The specific signal (ie, phosphorylated
p42/44 MAP kinase or Egr-1) was then corrected for any unequal
protein content between lanes by stripping the membrane and
reprobing for a constitutive control protein (ie, total p42/44 or
-tubulin, respectively). The integrated density value ratio of
The Journal of Thoracphosphorylated p42/44 to total p42/44 or Egr-1 to -tubulin was
calculated and expressed as the mean  SD from 3 experiments.
IL-6 Enzyme-linked Immunosorbent Assay
HUVECs were treated for 4 hours with 0.15 U/mL thrombin in the
presence or absence of 1600 KIU/mL aprotinin. Supernatants were
collected at 4 hours, centrifuged to remove cell debris, and assayed
for IL-6 levels by using the enzyme-linked immunosorbent assay
technique (Duosets; R&D Systems, Abingdon, United Kingdom),
according to the manufacturer’s recommendations. Results are
expressed as the mean IL-6 concentration (in picograms per mil-
liliter)  SD from 7 experiments.
Statistics
Statistical comparisons between thrombin- and aprotinin-treated
conditions were analyzed by using a paired Student t test.
Results
PAR1 Receptor Cleavage
The 7-transmembrane thrombin receptor PAR1 is activated
by proteolytic cleavage of its exodomain, causing G protein–
coupled signaling into the cell.6 PAR1 activation was mon-
Figure 1. Effect of aprotinin on protease-activated receptor 1
(PAR1) receptor cleavage. Human umbilical vein endothelial cells
were treated in suspension with -thrombin (Tbn; 0.02 U/mL) for
10 minutes at 37°C with or without aprotinin (Apr) at 200 KIU/mL.
Cleavage of PAR1 was monitored by means of flow cytometry with
an antibody, SPAN-12, that detects only the intact (ie, unactivated)
receptor. Results are expressed in units of relative fluorescent in-
tensity (RFI), which are calculated by dividing the mean fluorescent
staining intensity obtained with SPAN-12 antibody by the staining
intensity obtained with a class-matched (IgG1) control antibody.
Boxes show medians and quartiles, and whiskers indicate 5th
and 95th percentiles (n  9 experiments).itored by detecting receptor cleavage with an antibody,
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receptor. Proteolytic activation of PAR1 took place at low
concentrations of thrombin (0.02 U/mL) in cultured endo-
thelial cells and was abrogated by treatment with aprotinin
at 200 KIU/mL (Figure 1).
Calcium Flux
Thrombin induction of intracellular Ca2 flux was mea-
sured as an indicator of PAR1 signal transduction.10,22 Ca2
fluxes were monitored spectrofluorimetrically in Fura-2–
loaded cells, revealing a sharp calcium spike at 20 seconds
after stimulation with thrombin used at 0.15 U/mL (Figure
2, A). This was completely abrogated by pretreatment with
1600 KIU/mL aprotinin (Figure 2, B). PAR1 receptors
remained competent for signaling, however, because by-
passing the proteolytic cleavage step with the synthetic
activating peptide TRAP-6 induced a robust Ca2 flux.
Therefore inhibition of PAR1 cleavage by aprotinin abro-
gated thrombin-induced Ca2 signals in endothelial cells.
p42/44 MAP Kinase Signaling Protein Activation
One of the key signaling pathways activated by thrombin is
the MAP kinase pathway, which includes the p42/44 fam-
ily.13,14 To investigate whether aprotinin inhibits this path-
way, phosphorylation of p42/44 was studied as a measure
of activation. Activation of the p42/44 kinase, as detected
Figure 2. Effect of aprotinin (Apr) on thrombin (Tbn)–in
cells in suspension were loaded with the calcium
calcium fluxes spectrophotometrically after additio
(1600 KIU/mL; B) and thrombin receptor–activating p
similar experiments.by means of Western immunoblotting with a phospho-
24 The Journal of Thoracic and Cardiovascular Surgery ● Januaspecific anti-p42/44 antibody, was induced by incubation
of HUVECs with thrombin (0.15 U/mL) for 10 minutes.
Aprotinin (1600 KIU/mL) suppressed thrombin-dependent
phosphorylation of p42/44 (Figure 3, A). A ratio of phos-
phorylated versus total p42/44 protein was determined from
densitometric scanning of blots to quantitate activation of
p42/44 by thrombin and to confirm the inhibitory effect of
aprotinin (Figure 3, B).
Egr-1 Transcription Factor Upregulation
Activation of p42/44 MAP kinase by thrombin is known to
increase expression of the transcription factor Egr-1.14 We
therefore investigated Egr-1 protein levels in HUVECs by
means of Western blot analysis, with -tubulin as a
loading control. This revealed upregulation of Egr-1 at 1
hour after thrombin addition (0.15 U/mL); however, this
effect was abrogated in the presence of 1600 KIU/mL
aprotinin (Figure 4).
IL-6 Secretion
Having demonstrated that aprotinin can inhibit thrombin-
dependent signaling in endothelial cells, we set out to de-
termine whether this inhibition could have functional rele-
vance. An important target downstream of Egr-1 is the
proinflammatory cytokine IL-6, which is strongly induced
clinically after CPB.18,19 IL-6 levels were therefore deter-
d calcium fluxes. Human umbilical vein endothelial
rophore Fura-2 AM and monitored for intracellular
thrombin (0.15 U/mL; A) or thrombin plus aprotinin
e 6 (TRAP-6). Traces shown are representative of 3duce
fluo
n of
eptidmined in HUVEC culture supernatants. This demonstrated
ry 2006
Day et al Cardiopulmonary Support and Physiology
CS
Pthat thrombin (0.15 U/mL) induced IL-6 secretion at 4
hours; however, aprotinin (1600 KIU/mL) significantly in-
hibited this secretion (Figure 5).
Discussion
The anti-inflammatory properties of aprotinin in CPB have
been recognized for more than 10 years26-29; however, the
molecular mechanisms through which this is achieved have
remained elusive. Inhibition of contact activation of platelets
Figure 3. Effect of aprotinin (Apr) on thrombin (Tbn)–induced
phosphorylation of p42/44 mitogen-activated protein kinase sig-
naling protein. A, Endothelial cells were stimulated with throm-
bin (0.15 U/mL) or thrombin plus 1600 KIU/mL aprotinin for 10
minutes before lysis and immunoblotting for phosphorylated (ie,
activated) p42/44 mitogen-activated protein kinase signaling pro-
tein. After detection with a horseradish peroxidase–conjugated
secondary antibody and chemiluminescence, blots were
stripped and reprobed for total p42/44 protein. B, The intensity
of each band, in units of integrated density value (IDV), was
determined from densitometric scanning of blots, and the ratio
of phosphorylated versus total p42/44 protein is shown as the
mean IDV ratio  standard deviation from 3 experiments.and neutrophils, indirect effects through kallikrein inhibi-
The Journal of Thoraction, and blockade of leukocyte extravasation have all been
proposed on the basis of experimental models of inflamma-
tion.26,28-32 Clinically, aprotinin also diminishes neutrophil
accumulation and IL-8 secretion in the lung after CPB.33
However, specific receptor mechanisms have only been
recognized on platelets through targeting of the PAR1
receptor in vitro and in vivo.22-24 Because the same
receptor is present on endothelial cells and mediates proin-
flammatory signaling pathways due to thrombin, the pres-
ent study examined whether aprotinin targeted endothelial
PAR1 in vitro.
We have demonstrated that a cascade of thrombin-induced
signaling events in cultured endothelial cells, involving PAR1
Figure 4. Effect of aprotinin (Apr) on thrombin (Tbn)–induced
early growth response 1 (Egr-1) transcription factor upregulation.
A, Endothelial cells were stimulated with thrombin (0.15 U/mL) or
thrombin plus 1600 KIU/mL aprotinin for 1 hour before lysis and
immunoblotting for Egr-1 protein. -Tubulin is shown as a loading
control. B, The ratio of Egr-1/-tubulin protein was measured by
means of densitometric scanning of blots and is shown as the
mean integrated density value ratio (IDV)  standard deviation
from 3 experiments.receptor cleavage, Ca2 flux, p42/44 phosphorylation, Egr-1
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The initial receptor cleavage event was blocked at 200
KIU/mL aprotinin, which is equivalent to the full dose
regimen used clinically in CPB. Higher concentrations of
aprotinin (1600 KIU/mL) were needed to block other down-
stream signaling events, but this might have been an artifact
of the in vitro model system because 8-fold higher concen-
trations of thrombin were needed for downstream signaling
in endothelial cells. The need for higher thrombin levels to
fully activate signaling pathways might be due to a higher
signaling threshold in cultured HUVECs, as previously rec-
ognized.14 This represents a limitation of the present study,
and it will be important to validate the molecular mecha-
nisms identified here in vivo at clinically relevant doses of
aprotinin.
Experiments with the anti-PAR1 antibody SPAN-12 and
calcium flux show that aprotinin blocks the receptor cleav-
age step in PAR1 activation. Inhibition of calcium flux was
restored in the presence of the agonist polypeptide TRAP-6.
Because TRAP-6 bypasses the need for receptor cleavage
during activation, this demonstrates unequivocally that aproti-
nin targets the proteolytic cleavage step in PAR1 activation.
This is the same mechanism of action as described in plate-
lets22,23; however, it is distinct from the peptidomimetic
class of PAR1 antagonists, which do not affect receptor
Figure 5. Effect of aprotinin (Apr) on thrombin (Tbn)–induced
interleukin 6 (IL-6) secretion. Endothelial cell monolayers were
established in 25-cm2 flasks and stimulated for 4 hours in the
presence of thrombin (0.15 U/mL) with or without 1600 KIU/mL
aprotinin. Supernatants were collected, and levels of secreted
IL-6 were determined by means of enzyme-linked immunosorbent
assay. Boxes show medians and quartiles, and whiskers indicate
5th and 95th percentiles (n  7 experiments).cleavage but block signal transduction.15,16 As stated pre-
26 The Journal of Thoracic and Cardiovascular Surgery ● Januaviously,23 we do not believe that aprotinin directly inhibits
the serine protease catalytic activity of thrombin in solution
because it has a low inhibitory constant for thrombin,34 and
our working hypothesis is that aprotinin blocks the rate-
limiting step of thrombin binding to the PAR1 receptor.
The anti-inflammatory potency of aprotinin on endo-
thelial cells is underlined by its inhibition of IL-6 secre-
tion, a potent proinflammatory cytokine upregulated dur-
ing bypass.18,19 Interestingly, there might also be a link
between IL-6 and neurodegeneration and stroke. A pro-
moter polymorphism in IL-6 is overrepresented in patients
with a history of ischemic stroke, and high plasma IL-6
levels are associated with neurologic worsening immedi-
ately after stroke.35,36 Although the source of IL-6 after
bypass is unclear, therapeutic blockade of endothelial PAR1
fits well as a molecular mechanism to explain, at least in
part, the anti-inflammatory and antistroke properties re-
ported for aprotinin clinically.26,27,29,33,37
In conclusion, our results provide the first evidence that
endothelial PAR1 can be targeted by aprotinin, as on plate-
lets. Although further studies will be required to validate
this mechanism of action in vivo, it is likely that endo-
thelial PAR1 blockade might explain many of the anti-
inflammatory properties of this drug reported clinically.
We thank Dr Sussan Nourshargh for assistance with calcium
fluorimetry experiments.
References
1. Boisclar MD, Lane DA, Philippou H, Sheikh S, Hunt B. Thrombin
production, inactivation and expression during open heart surgery
measured by assays for activation fragments including new ELISA for
prothrombin fragment F1  2. Thromb Haemost. 1993;70:253-8.
2. Brister SJ, Ofosu FA, Buchanan MR. Thrombin generation during
cardiac surgery: is heparin the ideal anticoagulant? Thromb Haemost.
1993;70:259-62.
3. Boyle EM, Verrier ED, Spiess BD. Endothelial cell injury in cardio-
vascular surgery: the procoagulant response. Ann Thorac Surg. 1996;
62:1549-57.
4. Ferraris VA, Ferraris SP, Singh A, et al. The platelet thrombin receptor
and postoperative bleeding. Ann Thorac Surg. 1998;65:352-8.
5. Olsen EE, Lyuboslavsky P, Traynelis SF, McKeon RJ. PAR1 defi-
ciency protects against neuronal damage and neurologic deficits after
unilateral cerebral hypoxia/ischemia. J Cereb Blood Flow Metab.
2004;24:964-71.
6. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a
functional thrombin receptor reveals a novel proteolytic mechanism of
receptor activation. Cell. 1991;64:1057-68.
7. Vassallo RR Jr, Kieber-Emmons T, Cichowski K, Brass LF. Structure-
function relationships in the activation of platelet thrombin receptors
by receptor-derived peptides. J Biol Chem. 1992;267:6081-5.
8. Molino M, Woolkalis MJ, Reavey-Cantwell J, et al. Endothelial cell
thrombin receptors and PAR-2. Two protease-activated receptors
located in a single cellular environment. J Biol Chem. 1997;272:
11133-41.
9. Kranzhofer R, Clinton SK, Ishii K, Coughlin SR, Fenton JW 2nd,
Libby P. Thrombin potently stimulates cytokine production in human
vascular smooth muscle cells but not in mononuclear phagocytes. Circ
Res. 1996;79:286-94.
10. Kahn ML, Nakanishi MM, Shapiro MJ, Ishihara H, Coughlin SR.
Protease-activated receptors 1 and 4 mediate activation of human
platelets by thrombin. J Clin Invest. 1999;103:879-87.
ry 2006
Day et al Cardiopulmonary Support and Physiology
CS
P11. Junge CE, Sugawara T, Mannaioni G, et al. The contribution of
protease-activated receptor 1 to neuronal damage caused by tran-
sient focal cerebral ischemia. Proc Natl Acad Sci U S A. 2003;100:
13019-24.
12. Kaplanski G, Marin V, Fabrigoule M, et al. Thrombin-activated human
endothelial cells support monocyte adhesion in vitro following expres-
sion of intercellular adhesion molecule-1 (ICAM-1; CD54) and vas-
cular cell adhesion molecule-1 (VCAM-1; CD106). Blood. 1998;92:
1259-67.
13. Lidington EA, Haskard DO, Mason JC. Induction of decay-accelerating
factor by thrombin through a protease-activated receptor 1 and protein
kinase C-dependent pathway protects vascular endothelial cells from
complement-mediated injury. Blood. 2000;96:2784-92.
14. Wu SQ, Minami T, Donovan DJ, Aird WC. The proximal serum
response element in the Egr-1 promoter mediates response to thrombin
in primary human endothelial cells. Blood. 2002;100:4454-61.
15. Andrade-Gordon P, Derian CK, Maryanoff BE, et al. Administration
of a potent antagonist of protease-activated receptor-1 (PAR1) atten-
uates vascular restenosis following balloon angioplasty in rats. J Phar-
macol Exp Ther. 2001;298:34-42.
16. Covic L, Misra M, Badar J, Singh C, Kuliopulos A. Pepducin-based
intervention of thrombin-receptor signaling and systemic platelet ac-
tivation. Nat Med. 2002;8:1161-5.
17. Kerr R, Sterlin D, Ludlam CA. Interleukin-6 and haemostasis. Br J
Haematol. 2001;115:3-12.
18. Steinberg JB, Kapelanski DP, Olson JD, Weiler JM. Cytokine and
complement levels in patients undergoing cardiopulmonary bypass.
J Thorac Cardiovasc Surg. 1993;106:1008-16.
19. Voisine P, Ruel M, Khan TA, et al. Differences in gene expression
profiles of diabetic and nondiabetic patients undergoing cardiopulmo-
nary bypass and cardioplegic arrest. Circulation. 2004;110(suppl II):
II280-6.
20. Gaudino M, Andreotti F, Zamparelli R, et al. The -174G/C interleukin-6
polymorphism influences postoperative interleukin-6 levels and post-
operative atrial fibrillation. Is atrial fibrillation an inflammatory com-
plication? Circulation. 2003;108(suppl II):II195-9.
21. Marin V, Montero-Julian FA, Gres S, et al. The IL-6-soluble IL-
6Ralpha autocrine loop of endothelial activation as an intermediate
between acute and chronic inflammation: an experimental model in-
volving thrombin. J Immunol. 2001;167:3435-42.
22. Poullis M, Manning R, Laffan M, Haskard DO, Taylor KM, Landis
RC. The anti-thrombotic effect of aprotinin: actions mediated through
the protease-activated receptor 1. J Thorac Cardiovasc Surg. 2000;
120:370-8.
23. Day JRS, Punjabi PP, Haskard DO, Landis RC, Taylor KM. Clinical
inhibition of the seven-transmembrane thrombin receptor (PAR1) by
intravenous aprotinin during cardiothoracic surgery. Circulation. 2004;The Journal of Thorac24. Khan TA, Bianchi C, Voisine P, Sandmeyer J, Feng J, Sellke FW.
Aprotinin inhibits protease-dependent platelet aggregation and throm-
bosis. Ann Thorac Surg. 2005;79:1545-50.
25. Philippidis P, Mason JC, Evans BJ, Taylor KM, Haskard DO,
Landis RC. The hemoglobin scavenger receptor CD163 mediates
interleukin-10 release and heme oxygenase-1 synthesis: antiinflamma-
tory monocyte-macrophages responses in vitro, in resolving skin blis-
ters in vivo and postoperatively following cardio-pulmonary bypass.
Circ Res. 2004;94:119-26.
26. Hill GE, Alonso A, Spurzem JR, Stammers AH, Robbins RA. Apro-
tinin and methylprednisolone equally blunt neutrophil cardiopulmo-
nary bypass-induced inflammation in humans. J Thorac Cardiovasc
Surg. 1995;110:1658-62.
27. Gott JP, Cooper WA, Schmidt FE Jr, et al. Modifying risk for extra-
corporeal circulation: trial of four antiinflammatory strategies. Ann
Thorac Surg. 1998;66:747-53.
28. Wachtfogel YT, Kucich U, Hack CE, et al. Aprotinin inhibits the
contact, neutrophil, and platelet activation systems during simulated
extracorporeal perfusion. J Thorac Cardiovasc Surg. 1993;106:1-10.
29. Asimakopoulos G, Kohn A, Stefanou DC, Haskard DO, Landis RC,
Taylor KM. Leukocyte integrin expression in patients undergoing
cardiopulmonary bypass. Ann Thorac Surg. 2000;69:1192-7.
30. Asimakopoulos G, Thompson R, Nourshargh S, et al. An anti-
inflammatory property of aprotinin discovered at the level of leuko-
cyte extravasation. J Thorac Cardiovasc Surg. 2000;120:361-9.
31. Asimakopoulos G, Lidington EA, Mason JC, Haskard DO, Taylor
KM, Landis RC. Effect of aprotinin on endothelial cell activation.
J Thorac Cardiovasc Surg. 2001;122:123-7.
32. Pruefer D, Makowski J, Dahm M, et al. Aprotinin inhibits leukocyte-
endothelial cell interactions after hemorrhage and reperfusion. Ann
Thorac Surg. 2003;75:210-5.
33. Hill GE, Pohorecki R, Alonso A, Rennard SI, Robbins RA. Aprotinin
reduces interleukin-8 production and lung neutrophil accumulation
after cardiopulmonary bypass. Anesth Analg. 1996;83:696-700.
34. Pintigny D, Dachary-Prigent J. Aprotinin can inhibit the proteolytic
activity of thrombin. A fluorescence and an enzymatic study. Eur
J Biochem. 1992;207:89-95.
35. Pola R, Flex A, Gaetani E, Flore R, Serricchio M, Pola P. Synergistic
effect of 174 G/C polymorphism of the interleukin-6 gene promoter
and 469 E/K polymorphism of the intercellular adhesion molecule-1
gene in Italian patients with history of ischemic stroke. Stroke. 2003;
34:881-5.
36. Vila N, Castillo J, Davalos A, Esteve A, Planas AM, Chamorro A.
Levels of anti-inflammatory cytokines and neurological worsening in
acute ischemic stroke. Stroke. 2003;34:671-5.
37. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on
clinical outcomes in coronary artery bypass graft surgery: a systematic
review and meta-analysis of randomized clinical trials. J Thorac110:2597–600. Cardiovasc Surg. 2004;128:442-8.
The Journal of Thoracic and Cardiovascular Surgery Conflict of Interest Policy
To assure fairness to authors submitting work for consideration in The Journal of Thoracic and Cardiovas-
cular Surgery, a mechanism exists for managing conflicts of interest. The editor and each of the section editors
complete a “Conflict of Interest” form that identifies any and all relationships with commercial and other
academic entities. When the editor has a potential conflict because of a relationship with another entity or author,
the editor appoints an alternate editor from among the section editors or editorial board members who assumes
the entire responsibility for final decisions on the manuscript in question. The editor does not read the reviews
that are submitted nor engage in discussing the manuscript prior to the final decision. When the conflict of
interest involves a section editor, a “guest section editor” is appointed who fills the role normally played by the
conflicted section editor. All members of the editorial board and reviewers are asked to indicate any conflict of
interest when they agree to review a manuscript.ic and Cardiovascular Surgery ● Volume 131, Number 1 27
